Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA off-target sites with partial pegRNA complementarity refer to unintended locations within the genome where prime editing components bind and exert enzymatic activity. Prime editing utilizes a prime editing guide RNA (pegRNA) consisting of a spacer sequence for targeting and a 3' extension containing a primer binding site (PBS) and a reverse transcriptase template (RTT) (Anzalone et al., 2019). Off-target effects occur when these sequences hybridize with non-target DNA regions that possess high sequence similarity, leading to unintended nicks and genetic insertions or deletions (Doman et al., 2022). While prime editing is generally considered more precise than traditional CRISPR-Cas9, these off-target sites represent a significant safety concern in the development of gene therapies. Unintended modifications at these sites can result in genotoxicity, chromosomal rearrangements, or the disruption of essential genes, potentially leading to oncogenesis (Kim et al., 2020). Consequently, rigorous screening and computational modeling are employed to identify and minimize activity at these sites during the design of therapeutic pegRNAs.
Unintended hybridization of the pegRNA spacer or the 3' extension (primer binding site) to non-target genomic DNA sequences, which allows the Cas9 nickase-reverse transcriptase fusion protein to bind and execute unintended reverse transcription or nicking at incorrect loci (Anzalone et al., 2019; Doman et al., 2022).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA off-target sites with partial prime editing guide RNA (pegRNA) complementarity (pegRNA off-target sites).